# ICMJE DISCLOSURE FORM

**Date:** 8/18/2025

**Your Name:** Thomas W. Burke

**Manuscript Title:** Pediatric T cell and B cell responses to SARS-CoV-2 infection

**Manuscript Number (if known):** 196032-INS-CRPH-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | NIH grant funding | to Duke University |
| | | | |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ **None** | |
| | | See above | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☐ **None** | |
| | | Biomeme Inc (consulting) | Payment in form of shares and share options in Biomeme Inc |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☐ **None** | |
| | | Biomeme Inc – shares and share options | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 8/18/2025

**Your Name:** Shane Crotty

**Manuscript Title:** Pediatric T cell and B cell responses to SARS-CoV-2 infection

**Manuscript Number (if known):** 196032-INS-CRPH-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☐ **None** | |
| | | NIH NIAID AI142742 | LJI |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 8/18/2025

**Your Name:** Alba Grifoni

**Manuscript Title:** Pediatric T cell and B cell responses to SARS-CoV-2 infection

**Manuscript Number (if known):** 196032-INS-CRPH-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 8/17/2025

**Your Name:** L. Benjamin Hills

**Manuscript Title:** Pediatric T cell and B cell responses to SARS-CoV-2 infection

**Manuscript Number (if known):** 196032-INS-CRPH-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 8/17/2025

**Your Name:** Jillian H. Hurst

**Manuscript Title:** Pediatric T cell and B cell responses to SARS-CoV-2 infection

**Manuscript Number (if known):** 196032-INS-CRPH-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☐ **None** | |
| | | National Institute for Allergy and Infectious Diseases (*K01-AI173398)* | |
| | | National Institute for Allergy and Infectious Diseases (*R01-AI161008)* | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 8/17/2025

**Your Name:** Matthew S. Kelly

**Manuscript Title:** Pediatric T cell and B cell responses to SARS-CoV-2 infection

**Manuscript Number (if known):** 196032-INS-CRPH-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| **Time frame: Since the initial planning of the work** | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☐ **None** | |
| | | Merck & Co., Inc. | Payments made to institution for research grant MISP #60495. |
| | | National Institutes of Health | Payments made to institution for research grants R01-AI161008 and K23-AI135090. |
| | | | Click the tab key to add additional rows. |
| **Time frame: past 36 months** | | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☐ **None** | |
| | | Merck & Co., Inc. | Payments made to me for consulting fees. |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 8/18/2021

**Your Name:** Alexandre T Rotta

**Manuscript Title:** Pediatric T cell and B cell responses to SARS-CoV-2 infection

**Manuscript Number (if known):** 196032-INS-CRPH-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ **None** | |
| | | Phillips Healthcare | Payments made to my institution |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☐ **None** | |
| | | Elsevier | Payments made to me |
| | | Springer | Payments made to me |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☐ **None** | |
| | | Breas US | Payments made to me |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☐ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☐ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 8/26/2021

**Your Name:** Alessandro Sette

**Manuscript Title:** Pediatric T cell and B cell responses to SARS-CoV-2 infection

**Manuscript Number (if known):** 196032-INS-CRPH-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| **6** | Payment for expert testimony | ☒ **None** | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 8/19/2025

**Your Name:** Nicholas A. Turner

**Manuscript Title:** Pediatric T cell and B cell responses to SARS-CoV-2 infection

**Manuscript Number (if known):** 196032-INS-CRPH-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ **None** | |
| | | NIH/ARLG | Research/training grant |
| | | PDI | Research contract |
| | | Purio | Research contract |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☐ **None** | |
| | | AMMI Canada | Speaker honoraria for Staph bacteremia review |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 8/19/2025

**Your Name:** Daniela Weiskopf

**Manuscript Title:** Pediatric T cell and B cell responses to SARS-CoV-2 infection

**Manuscript Number (if known):** 196032-INS-CRPH-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ None | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ **None** | |
| | | Contract No. 75N93019C00065 to A.S, D.W. | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☐ **None** | |
| | | DW is a consultant for Moderna | |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☐ **None** | |
| | | Honorarium to teach at the AAI introductory course (2023-2025) - $200/year | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☐ **None** | |
| | | LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☐ **None** | |
| | | FASEB Science Policy Committee - AAI representative at **Federation of American Societies for Experimental Biology (FASEB)**! | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 8/18/2025

**Your Name:** Sallie Permar

**Manuscript Title:** Pediatric T cell and B cell responses to SARS-CoV-2 infection

**Manuscript Number (if known):** 196032-INS-CRPH-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ **None** | |
| | | Dynavax | amount received is < $5000 |
| | | Moderna | amount received is < $5000 |
| | | Pfizer | amount received is < $5000 |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☐ **None** | |
| | | Dynavax | Individual consulting fees amount received is < $5000 |
| | | Moderna | Individual consulting fees amount received is < $5000 |
| | | Pfizer | Individual consulting fees amount received is < $5000 |
| | | GlaxoSmithKline | Individual consulting fees amount received is < $5000 |
| | | Imunon | Individual consulting fees amount received is < $5000 |
| | | Merck | Individual consulting fees amount received is < $5000 |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in | ☒ **None** | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| | other board, society, committee or advocacy group, paid or unpaid | | |
| **11** | Stock or stock options | ☒ **None** | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| **13** | Other financial or non-financial interests | ☒ **None** | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 8/19/2025

**Your Name:** Elizabeth A Petzold

**Manuscript Title:** Pediatric T cell and B cell responses to SARS-CoV-2 infection

**Manuscript Number (if known):** 196032-INS-CRPH-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☐ **None** | |
| | | NIH grant funding | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ **None** | |
| | | As above | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 8/21/2025

**Your Name:** Yvonne Dogariu

**Manuscript Title:** Pediatric T cell and B cell responses to SARS-CoV-2 infection

**Manuscript Number (if known):** 196032-INS-CRPH-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 8/21/2025

**Your Name:** Genevieve Fouda

**Manuscript Title:** Pediatric T cell and B cell responses to SARS-CoV-2 infection

**Manuscript Number (if known):** 196032-INS-CRPH-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☐ **None** | |
| | | **1R01-AI161008-01A1** | NIH grant |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

**Date:** 8/21/2025

**Your Name:** Amber Myers

**Manuscript Title:** Pediatric T cell and B cell responses to SARS-CoV-2 infection

**Manuscript Number (if known):** 196032-INS-CRPH-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
|---|---|---|---|
| | | **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | ☒ **None** | |
| | | | |
| | | | |
| | | | Click the tab key to add additional rows. |
| | | **Time frame: past 36 months** | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **3** | Royalties or licenses | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **4** | Consulting fees | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| | | | |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **6** | Payment for expert testimony | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **7** | Support for attending meetings and/or travel | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **8** | Patents planned, issued or pending | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ **None** | |
| | | | |
| | | | |
| | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| **11** | Stock or stock options | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ **None** | |
| | | | |
| | | | |
| | | | |
| **13** | Other financial or non-financial interests | ☒ **None** | |
| | | | |
| | | | |
| | | | |

**Please place an "X" next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.